{
  "id": 19518054,
  "title": "Jefferies reiterates Regeneron stock rating ahead of patent hearing",
  "url": "https://urgent.news/2026/11/11/jefferies-reiterates-regeneron-stock-rating-ahead-of-patent-hearing",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-11T16:12:51.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/jefferies-reiterates-regeneron-stock-rating-ahead-of-patent-hearing-93CH-5019543"
  },
  "original_language": "en",
  "account": "Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) received a renewed Buy rating and a price target of $1,065 from Jefferies, in anticipation of a patent hearing scheduled for December 4th. The stock can be bought for $916, resulting in a market capitalization of $91.86 billion. Analyzing the stock, InvestingPro suggests that it is presently undervalued, with shares exhibiting a 29% increase over the past six months. This recommendation precedes a Patent Trial and Appeal Board hearing on Regeneron’s EYLEA HD ’036 patent, which may secure protection until 2039. The hearing will focus on crucial elements of EYLEA HD’s 8mg formulation. In response to Alvotech’s petition for post-grant review, which explored the possibility of withdrawal without adverse judgment, Regeneron declined to accept the withdrawal request. The Patent Trial and Appeal Board is projected to render its final decision by March 3rd, 2027. The '036 patent encompasses vital components of EYLEA HD’s 8mg formulation. Jefferies' assessment includes a key opinion leader estimate indicating a 60% to 70% likelihood of Regeneron emerging victorious in the patent dispute. In line with the optimistic outlook, data from InvestingPro reveals that 20 analysts have revised their earnings estimates upwards for the upcoming period. To gain further insights, investors can purchase Regeneron’s comprehensive Pro Research Report, which is one of over 1,400 reports available on the platform. Recently, Regeneron Pharmaceuticals announced robust third-quarter earnings, with total revenue amounting to $5.116 billion, surpassing Guggenheim's estimate of $4.722 billion and the consensus forecast of $4.597 billion. Non-GAAP earnings per share stood at $20.07, exceeding Guggenheim's forecast of $17.68 and the consensus estimate of $16.33. The company's success can be attributed to its collaboration products, which include Dupixent, Eylea, and Libtayo, leading to the revenue surpassing expectations. In response to these results, several investment firms have adjusted their price targets for Regeneron. Cantor Fitzgerald raised its target to $980, highlighting Dupixent's strong performance in the previous quarter. Truist Securities also increased its target to $982, emphasizing the company's financial achievements, as its earnings and revenue exceeded projections. BofA Securities revised its target to $1,030, acknowledging the 12% revenue improvement compared to both its previous assessment and the consensus. Guggenheim set a new price target of $1,100 and maintained a Buy rating, appreciating the company's exceptional quarterly results. Furthermore, Wells Fargo raised its price target to $925, focusing on Regeneron's effective commercial strategy. The analysts from these firms have consistently expressed confidence in Regeneron's future performance, citing recent developments. This report was produced with the assistance of AI and subsequently reviewed by an editor. Additional details can be found in the Terms and Conditions.",
  "summary": null,
  "key_points": [
    "Jefferies upgrades Regeneron to Buy with $1,065 price target",
    "Patent hearing on EYLEA HD 036 patent set for December 4th",
    "Analysts project 60% to 70% chance of victory in patent dispute"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}